1
                 SECURITIES AND EXCHANGE COMMISSION
    
                      Washington, D.C.  20549
    
                           FORM 8-K
    
                         CURRENT REPORT
    
    
                 PURSUANT TO SECTION 13 OR 15(d) OF
                 THE SECURITIES EXCHANGE ACT OF 1934
    
    
    Date of Report (Date of earliest event reported)-September 11,1996
    
               ADVANCED VIRAL RESEARCH CORP.            
       (Exact name of registrant as specified in its charter)
    
         Delaware                  33-2262-A         59-2646820       
    (State or other juris-     (Commission File     (IRS Employer
    diction of incorporation)      Number)          Identification No.)
    
               1250 East Hallandale Beach Blvd.,  Suite 501
               Hallandale, Florida                    33009   
       (Address or principal executive offices)     (Zip Code)
    
    
    Registrant's telephone number, including area code: (954)458-7636
    
    
                           None
    (Former name or former address, if changed since last report)
  
  2
  
    Item 1.    Changes in Control of Registrant
    
          Not Applicable
    
    Item 2.    Acquisition or Disposition of Assets
    
          Not Applicable
    
    Item 3.    Bankruptcy or Receivership
    
          Not Applicable
   
    Item 4.    Changes in Registrant's Certifying Accountant
    
          Not Applicable
    
    Item 5.    Other Events
  
     On September 11, 1996, Advanced Viral Research Corp. (the
  "Company") received a written translation (the "Translation") of a
  report, in part authored by Dr. Juan Carlos Flichman, regarding
  certain results reported by Dr. Flichman in connection with a
  clinical trial assessing the efficacy of the Company's drug
  Reticulose on the Humanopapilloma Virus (the "Clinical Trial").  The
  Clinical Trial was conducted under Dr. Flichman's supervision in a
  hospital located in Buenos Aires, Argentina pursuant to a protocol
  developed by Dr. Flichman. 
  
     The Translation provides that 20 persons (6 males and 14
  females) diagnosed to be infected with HPV were treated topically
  with Reticulose.  The Translation concludes that based on the
  remissions and the clinical improvement observed in 50% of the
  patients, the Translation recommends and encourages that Reticulose
  be used as an alternative in biological treatment in Humanopapilloma
  Viruses. 
  
     A copy of the translation is provided as Exhibit 1 to this
  Current Report of Form 8-K.  
  
    Item 6. Resignations of Registrant's Directors
    
            Not Applicable
    
    Item 7. Financial Statements and Exhibits
    
          (a)  Financial statements of business acquired
    
               None
    
          (b)  Pro forma financial information
    
               None
    
          (c)  Exhibits
  
          (1)  Report, translated from Spanish to English,
  authored by Dr. Juan Carlos Flichman regarding certain results in
  connection with a clinical trial assessing the efficacy of the
  Company's drug Reticulose on the Humanpapilloma Virus.
  
  
    Item 8. Change in Fiscal Year
    
            Not Applicable
    
      3
                           SIGNATURES
    
     Pursuant to the requirements of the Securities Exchange Act of
  1934, the registrant has duly caused this report to be signed on its
  behalf by the undersigned hereunto duly authorized.
    
    
                              ADVANCED VIRAL RESEARCH CORP.     
  
                              (Registrant)
    
    
    
    Dated: September 25, 1996       By: /s/ William Bregman      
                                        William Bregman
                                        Secretary-Treasurer
    
    
    
    
      4
  
                      LIST OF EXHIBITS
    
  
          (1)  Report, translated from Spanish to English,
  authored by Dr. Juan Carlos Flichman regarding certain results in
  connection with a clinical trial assessing the efficacy of the
  Company's drug Reticulose on the Humanpapilloma Virus.